Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Disorders of Hemostasis

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Rh Blood Group

Rh Blood Group

The Rhesus (Rh) antigen is crucial in determining blood groups and ensuring compatibility during blood transfusions.

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

Extrinsic and Intrinsic Pathways of Hemostasis

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Blood Group O Does Not Increase the Risk of Inhibitors in Severe Haemophilia A: Data from the PedNet Study Group.

Haemophilia : the official journal of the World Federation of Hemophilia·2025

Same author

Hemophilia B Leyden: characteristics and natural history in the International Pediatric Network of Hemophilia Management Registry.

Journal of thrombosis and haemostasis : JTH·2025

Same author

BAY 81-8973 Demonstrates Long-Term Safety and Efficacy in Children With Severe Haemophilia A: Results From the LEOPOLD Kids Extension Study.

European journal of haematology·2024

Same author

Origin of pathogenic variant and mosaicism in families with a sporadic case of haemophilia B.

Haemophilia : the official journal of the World Federation of Hemophilia·2024

Same author

Prophylactic Treatment of Children with Hemophilia in Sweden.

Seminars in thrombosis and hemostasis·2024

Same author

Recombinant factor IX Fc for the treatment of hemophilia B.

European journal of haematology·2024

Search research articles

Related Experiment Video

Updated: May 17, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

Hemophilia and prophylaxis.

¹Departments of Pediatrics, Malmö & Lund and Malmö Centre for Thrombosis and Haemostasis, Skåne University Hospital, Lund University, Malmö, Sweden. rolf.ljung@med.lu.se

Pediatric Blood & Cancer

|October 31, 2012

Summary

Prophylactic treatment for hemophilia is superior to on-demand treatment for reducing bleeds and joint damage. Individualized prophylaxis, started early in children, is the optimal approach for hemophilia management.

Area of Science:

Hematology
Pediatric Medicine
Pharmacology

Background:

Hemophilia treatment has evolved from managing bleeds to preventing them.
On-demand treatment is less effective than prophylaxis for long-term joint health and bleed prevention.
Clinical evidence supports the superiority of prophylactic regimens over on-demand strategies.

Purpose of the Study:

To review the evidence supporting prophylactic treatment for hemophilia.
To compare prophylactic treatment with on-demand treatment.
To discuss future directions in hemophilia prophylaxis.

Main Methods:

Review of retrospective and prospective studies.
Analysis of clinical experience over decades.
Examination of outcomes related to joint bleeds, life-threatening bleeds, and arthropathy.

More Related Videos

Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection

Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection

Published on: February 2, 2018

Related Experiment Videos

Last Updated: May 17, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection

Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection

Published on: February 2, 2018

Main Results:

Prophylactic treatment significantly reduces joint bleeds and life-threatening hemorrhages compared to on-demand treatment.
Early initiation of prophylaxis (primary prophylaxis) in children is crucial for optimal outcomes.
Individualized prophylaxis, considering bleeding phenotype and arthropathy susceptibility, is recommended.

Conclusions:

Prophylactic treatment is the preferred standard of care for hemophilia, despite higher costs.
Individualized and early-initiated prophylaxis offers the best outcomes for hemophilia patients.
Future trends include advanced monitoring using global coagulation assays and pharmacokinetic parameters.